Survival Benefit of the Primary Prevention Implantable Cardioverter-Defibrillator Among Older Patients Does Age Matter? An Analysis of Pooled Data From 5 Clinical Trials

被引:81
作者
Hess, Paul L. [1 ]
Al-Khatib, Sana M. [1 ]
Han, Joo Y. [2 ]
Edwards, Rex [1 ]
Bardy, Gust H. [2 ]
Bigger, J. Thomas [3 ]
Buxton, Alfred [4 ]
Cappato, Riccardo [5 ]
Dorian, Paul [6 ]
Hallstrom, Al [2 ]
Kadish, Alan H. [7 ]
Kudenchuk, Peter J. [2 ]
Lee, Kerry L. [1 ]
Mark, Daniel B. [1 ]
Moss, Arthur J. [8 ]
Steinman, Richard [3 ]
Inoue, Lurdes Y. T. [2 ]
Sanders, Gillian [1 ]
机构
[1] Duke Clin Res Inst, Durham, NC 27715 USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Columbia Univ, New York, NY USA
[4] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[5] IRCCS Policlin San Donato, Milan, Italy
[6] Univ Toronto, Toronto, ON M5S 1A1, Canada
[7] Northwestern Feinberg Sch Med, Chicago, IL USA
[8] Univ Rochester, Rochester, NY USA
来源
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES | 2015年 / 8卷 / 02期
基金
美国医疗保健研究与质量局;
关键词
aging; defibrillators; implantable; meta-analysis; CARDIAC RESYNCHRONIZATION THERAPY; HEART-FAILURE; PROPHYLACTIC IMPLANTATION; MYOCARDIAL-INFARCTION; HOSPITAL READMISSION; AMERICAN-COLLEGE; SUDDEN-DEATH; HIGH-RISK; METAANALYSIS; ASSOCIATION;
D O I
10.1161/CIRCOUTCOMES.114.001306
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background-The impact of patient age on the risks of death or rehospitalization after primary prevention implantable cardioverter-defibrillator (ICD) placement is uncertain. Methods and Results-Data from 5 major ICD trials were merged: the Multicenter Automatic Defibrillator Implantation Trial I (MADIT-I), the Multicenter UnSustained Tachycardia Trial (MUSTT), the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II), the Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation Trial (DEFINITE), and the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Median age at enrollment was 62 (interquartile range 53-70) years. Compared with their younger counterparts, older patients had a greater burden of comorbid illness. In unadjusted exploratory analyses, ICD recipients were less likely to die than nonrecipients in all age groups: among patients aged <55 years: hazard ratio 0.48, 95% posterior credible interval 0.33 to 0.69; among patients aged 55 to 64 years: hazard ratio 0.69, 95% posterior credible interval 0.53 to 0.90; among patients aged 65 to 74 years: hazard ratio 0.67, 95% posterior credible interval, 0.53 to 0.85; and among patients aged >= 75 years: hazard ratio 0.54, 95% posterior credible interval 0.37 to 0.78. Sample sizes were limited among patients aged >= 75 years. In adjusted Bayesian-Weibull modeling, point estimates indicate ICD efficacy persists but is attenuated with increasing age. There was evidence of an interaction between age and ICD treatment on survival (two-sided posterior tail probability of no interaction <0.01). Using an adjusted Bayesian logistic regression model, there was no evidence of an interaction between age and ICD treatment on rehospitalization (two-sided posterior tail probability of no interaction 0.44). Conclusions-In this analysis, the survival benefit of the ICD exists but is attenuated with increasing age. The latter finding may be because of the higher burden of comorbid illness, competing causes of death, or limited sample size of older patients. There was no evidence that age modifies the association between ICD treatment and rehospitalization.
引用
收藏
页码:179 / 186
页数:8
相关论文
共 35 条
[1]
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure [J].
Bardy, GH ;
Lee, KL ;
Mark, DB ;
Poole, JE ;
Packer, DL ;
Boineau, R ;
Domanski, M ;
Troutman, C ;
Anderson, J ;
Johnson, G ;
McNulty, SE ;
Clapp-Channing, N ;
Davidson-Ray, LD ;
Fraulo, ES ;
Fishbein, DP ;
Luceri, RM ;
Ip, JH .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (03) :225-237
[3]
Comparison of Benefit and Mortality of Implantable Cardioverter-Defibrillator Therapy in Patients Aged ≥75 Years Versus Those &lt;75 Years [J].
Bruellmann, Simon ;
Dichtl, Wolfgang ;
Paoli, Ursula ;
Haegeli, Laurent ;
Schmied, Christian ;
Steffel, Jan ;
Brunckhorst, Corinna ;
Hintringer, Florian ;
Seifert, Burkhard ;
Duru, Firat ;
Wolber, Thomas .
AMERICAN JOURNAL OF CARDIOLOGY, 2012, 109 (05) :712-717
[4]
A randomized study of the prevention of sudden death in patients with coronary artery disease [J].
Buxton, AE ;
Lee, KL ;
Fisher, JD ;
Josephson, ME ;
Prystowsky, EN ;
Hafley, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (25) :1882-1890
[5]
Chen M-H., 2001, Bayesian Survival Analysis
[6]
Epstein AE, 2008, CIRCULATION, V117, P2820, DOI 10.1161/CIRCUALTIONAHA.108.189741
[7]
Implantable cardioverter-defibrillator prescription in the elderly [J].
Epstein, Andrew E. ;
Kay, G. Neal ;
Plumb, Vance J. ;
McElderry, H. Thomas ;
Doppalapudi, Harish ;
Yamada, Takumi ;
Shafiroff, Jeff ;
Syed, Zaffer A. ;
Shkurovich, Sergio .
HEART RHYTHM, 2009, 6 (08) :1136-1143
[8]
European Heart Rhythm Association, 2006, J Am Coll Cardiol, V48, pe247, DOI 10.1016/j.jacc.2006.07.010
[9]
Hospital readmission in patients treated with tiered-therapy implantable defibrillators [J].
Fahy, GJ ;
Sgarbossa, EB ;
Tchou, PJ ;
Pinski, SL .
CIRCULATION, 1996, 94 (06) :1350-1356
[10]
Improving Evidence-Based Care for Heart Failure in Outpatient Cardiology Practices Primary Results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) [J].
Fonarow, Gregg C. ;
Albert, Nancy M. ;
Curtis, Anne B. ;
Stough, Wendy Gattis ;
Gheorghiade, Mihai ;
Heywood, J. Thomas ;
McBride, Mark L. ;
Inge, Patches Johnson ;
Mehra, Mandeep R. ;
O'Connor, Christopher M. ;
Reynolds, Dwight ;
Walsh, Mary Norine ;
Yancy, Clyde W. .
CIRCULATION, 2010, 122 (06) :585-U114